Phone therapy shows promise for depression in ovarian cancer patients
NCT ID NCT00515372
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study looks at whether weekly phone counseling can help identify and treat depression in women with ovarian, peritoneal, or fallopian tube cancer. About 409 participants will either receive phone counseling or standard care with resource lists. The goal is to see which approach better improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Telephone counseling
- What this could lead to
- If successful, this could provide a simple, effective way to identify and treat depression in ovarian cancer patients, improving their quality of life.
- What could go wrong
- This is an early-phase behavioral study, so results may not be definitive. The intervention is phone-based, which may not work for everyone, and the study is not testing a drug or cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?
- Can a smart drug home in on Hard-to-Treat cancers?